木下 一郎 きのした いちろう 先生

来歴等

略歴

1988年 北海道大学 医学部 卒業、同内科学第一講座 入局
1997年 米国国立癌研究所 Cell and Cancer Biology部門 留学
2001年 北海道大学医学部附属病院 助手（第一内科）
2004年 北海道大学大学院 医学研究科 助手（腫瘍内科学分野）
2005年 北海道大学大学院 医学研究科 講師（腫瘍内科学分野）
2012年 北海道大学大学院 医学研究科 准教授（腫瘍内科学分野）
2019年 北海道大学病院 教授（がん遺伝子診断部）、がん遺伝子診断部長
2020年 北海道大学病院 腫瘍センター 副センター長

論文

• 1. Impact of clinical targeted sequencing on endocrine responsiveness in estrogen receptor-positive, HER2-negative metastatic breast cancer. Sci Rep. 2021 Apr 14;11(1):8109. doi: 10.1038/s41598-021-87645-6. PMID: 33854152; PMCID: PMC8047009.

  Hagio K, Amano T, Hayashi H, Takeshita T, Oshino T, Kikuchi J, Ohhara Y, Yabe I, Kinoshita I, Nishihara H, Yamashita H.

• 2. Clinical significance of comprehensive genomic profiling tests covered by public insurance in patients with advanced solid cancers in Hokkaido, Japan. Jpn J Clin Oncol. 2021 Apr 30;51(5):753-761. doi: 10.1093/jjco/hyaa277. PMID: 33532831.

  Kikuchi J, Ohhara Y, Takada K, Tanabe H, Hatanaka K, Amano T, C Hatanaka K, Hatanaka Y, Mitamura T, Kato M, Shibata Y, Yabe I, Endoh A, Komatsu Y, Matsuno Y, Sugiyama M, Manabe A, Sakurai A, Takahashi M, Naruse H, Torimoto Y, Dosaka- Akita H, Kinoshita I.

• 3. Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (edition 2.1). Int J Clin Oncol. 2021 Feb;26(2):233-283. doi: 10.1007/s10147-020-01831-6. PMID: 33249514; PMCID: PMC7819967.

  Naito Y, Aburatani H, Amano T, Baba E, Furukawa T, Hayashida T, Hiyama E, Ikeda S, Kanai M, Kato M, Kinoshita I, Kiyota N, Kohno T, Kohsaka S, Komine K, Matsumura I, Miura Y, Nakamura Y, Natsume A, Nishio K, Oda K, Oda N, Okita N, Oseto K, Sunami K, Takahashi H, Takeda M, Tashiro S, Toyooka S, Ueno H, Yachida S, Yoshino T, Tsuchihara K; Japanese Society of Medical Oncology; Japan Society of Clinical Oncology; Japanese Cancer Association.

• 4. Phase II trial of combination treatment with S-1/cetuximab in patients with platinum-ineligible recurrent and/or metastatic squamous cell carcinoma of the head and neck. Int J Clin Oncol. 2021 Jan;26(1):51-58. doi: 10.1007/s10147-020-01788-6. PMID: 32996023.

  Taguchi J, Shimizu Y, Ariga S, Goda T, Ohhara Y, Honma R, Noguchi T, Takeuchi S, Kinoshita I, Amano T, Mizumachi T, Kano S, Takahara M, Abe T, Homma A, Dosaka-Akita H.

• 5. Multiplex gene- panel testing for lung cancer patients. Pathol Int. 2020 Dec;70(12):921-931. doi: 10.1111/pin.13023. PMID: 32956529.

  Yatabe Y, Sunami K, Goto K, Nishio K, Aragane N, Ikeda S, Inoue A, Kinoshita I, Kimura H, Sakamoto T, Satouchi M, Shimizu J, Tsuta K, Toyooka S, Nishino K, Hatanaka Y, Matsumoto S, Mikubo M, Yokose T, Dosaka-Akita H.

• 6. Clinical impact of a cancer genomic profiling test using an in- house comprehensive targeted sequencing system. Cancer Sci. 2020 Oct;111(10):3926-3937. doi: 10.1111/cas.14608. PMID: 32772458; PMCID: PMC7540994.

  Hayashi H, Tanishima S, Fujii K, Mori R, Okada C, Yanagita E, Shibata Y, Matsuoka R, Amano T, Yamada T, Yabe I, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H.

• 7. DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail. Cancer Sci. 2019 May;110(5):1599-1608. doi: 10.1111/cas.13997. PMID: 30874360; PMCID: PMC6501010.

  Furuta M, Kikuchi H, Shoji T, Takashima Y, Kikuchi E, Kikuchi J, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J.

• 8. Bromodomain and extraterminal domain inhibition synergizes with WEE1-inhibitor AZD1775 effect by impairing nonhomologous end joining and enhancing DNA damage in nonsmall cell lung cancer. Int J Cancer. 2020 Feb 15;146(4):1114-1124. doi: 10.1002/ijc.32515. PMID: 31199520.

  Takashima Y, Kikuchi E, Kikuchi J, Suzuki M, Kikuchi H, Maeda M, Shoji T, Furuta M, Kinoshita I, Dosaka-Akita H, Sakakibara-Konishi J, Konno S.

• 9. Genomic testing for pancreatic cancer in clinical practice as real-world evidence. Pancreatology. 2018 Sep;18(6):647 654. doi: 10.1016/j.pan.2018.07.006.PMID: 30055942.

  Hayashi H, Tanishima S, Fujii K, Mori R, Okamura Y, Yanagita E, Matsuoka R, Amano T, Kinoshita I, Komatsu Y, Dosaka-Akita H, Nishihara H.

• 10. Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. ESMO Open. 2018 Feb 23;3(2):e000313. doi: 10.1136/esmoopen-2017-000313. PMID: 29531840; PMCID: PMC5844373.

  Oizumi S, Sugawara S, Minato K, Harada T, Inoue A, Fujita Y, Maemondo M, Watanabe S, Ito K, Gemma A, Demura Y, Fukumoto S, Isobe H, Kinoshita I, Morita S, Kobayashi K, Hagiwara K, Aiba K, Nukiwa T.

• 11. A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non small cell lung cancer (HOT1002). Cancer Chemother Pharmacol. 2017 Nov;80(5):955-963. doi: 10.1007/s00280-017-3432-4. PMID:28905108.

  Ikezawa Y, Asahina H, Oizumi S, Watanabe M, Takamura K, Kawai Y, Yamada N, Harada T, Kinoshita I, Fujita Y, Miyauchi E, Ogi T, Amano T, Furuta M, Sakakibara-Konishi J, Nishihara H, Dosaka-Akita H, Isobe H, Nishimura M; Hokkaido Lung Cancer Clinical Study Group.

• 12. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells. Cancer Sci. 2016 Jul;107(7):955-62. doi: 10.1111/cas.12957. PMID: 27116120; PMCID: PMC4946723.

  Takashina T, Kinoshita I, Kikuchi J, Shimizu Y, Sakakibara-Konishi J, Oizumi S, Nishimura M, Dosaka-Akita H.

• 13. Cancer stem-like cells derived from chemoresistant tumors have a unique capacity to prime tumorigenic myeloid cells. Cancer Res. 2014 May 15;74(10):2698-709. doi: 10.1158/0008-5472.CAN-13-2169. PMID: 24638980.

  Yamashina T, Baghdadi M, Yoneda A, Kinoshita I, Suzu S, Dosaka-Akita H, Jinushi M.

• 14. Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol. 2012 Sep;13(9):832-42. doi: 10.1038/ni.2376. PMID: 22842346; PMCID: PMC3622453.

  Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H, Fujioka Y, Ohba Y, Gorman JV, Colgan JD, Hirashima M, Uede T, Takaoka A, Yagita H, Jinushi M.

• 15. Minichromosome maintenance (MCM) protein 4 as a marker for proliferation and its clinical and clinicopathological significance in non-small cell lung cancer. Lung Cancer. 2011 May;72(2):229-37. doi: 10.1016/j.lungcan.2010.08.020. PMID: 20884074.

  Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Takeda K, Aburatani H, Oizumi S, Konishi J, Kaga K, Matsuno Y, Birrer MJ, Nishimura M, Dosaka-Akita H.

• 16. Distinctive expression of the polycomb group proteins Bmi1 polycomb ring finger oncogene and enhancer of zeste homolog 2 in nonsmall cell lung cancers and their clinical and clinicopathologic significance. Cancer. 2010 Jun 15;116(12):3015-24. doi: 10.1002/cncr.25128. PMID: 20564407.

  Kikuchi J, Kinoshita I, Shimizu Y, Kikuchi E, Konishi J, Oizumi S, Kaga K, Matsuno Y, Nishimura M, Dosaka-Akita H.

• 17. Gefitinib or chemotherapy for non-small- cell lung cancer with mutated EGFR. N Engl J Med. 2010 Jun 24;362(25):2380-8. doi: 10.1056/NEJMoa0909530. PMID: 20573926.

  Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T; North-East Japan Study Group.

著書

• 1. 【共著】肺癌：神経内分泌腫瘍, 180-183 (入門腫瘍内科学改訂第3版，篠原出版新社，東京），2020

• 2. 【共著】エピルビシン, 52-53（安全ながん薬物療法のために知っておきたい薬のハンドブック, ヴァンメディカル, 東京）, 2017

• 3. 【共著】ペメトレキセド, 164-165（安全ながん薬物療法のために知っておきたい薬のハンドブック, ヴァンメディカル, 東京）, 2017